The Multidisciplinary Support To Access living donor Kidney Transplant (MuST AKT) intervention: A Pilot Randomized Controlled Trial
Transplant International · 2026
DOI: 10.3389/ti.2026.15472 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Transplant International, 2026. Verfasst von Anne-Marie Selzler und 14 weiteren Autor:innen. Beteiligte Einrichtung: Medicine Strategic Clinical Network, Alberta Health Services, AB, Canada. Hauptthemen laut MEDLINE: Kidney Transplantation, Living Donors. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alberta Innovates - Health Solutions.
Abstract (Originalsprache)
We evaluated the feasibility and acceptability of the Multidisciplinary Support To Access living donor Kidney Transplant (MuST AKT) intervention, developed to increase living donor kidney transplantation (LDKT). In this pilot randomized controlled trial, we randomly assigned transplant candidates to receive standard care or the MuST AKT intervention, where transplant candidates and their social network addressed barriers to LDKT across four 60–90-minute sessions. Feasibility was assessed by consent/recruitment, retention, study protocol adherence, intervention adherence, and intervention engagement. Acceptability was assessed by questionnaire and post-intervention interviews. The recruitment rate was 61% (43/71), with 38 participants randomized 1:1. Among intervention participants, 1 was excluded for not meeting study criteria prior to start. Among those that started (18), 100% completed 1 session, 94% completed 2 sessions, 83% completed 3 sessions, and 56% completed all 4 sessions. The intervention was delivered in 71 days (mean), shorter than anticipated. The intervention participants reported increased confidence for communicating about LDKT from pre-to post-intervention, and all recommended MuST AKT to their peers. Intervention participants and invitees from their social network described a positive experience and provided recommendations for improvement. The MuST AKT intervention is feasible with minor modifications and acceptable to transplant candidates and their social network.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medicine Strategic Clinical Network, Alberta Health Services, AB, Canada.
- Adult Cystic Fibrosis, Kaye Clinic, Alberta Health Services, Edmonton, AB, Canada.
- Department of Medicine, University of Alberta, Edmonton, AB, Canada.
- Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
- Alberta Kidney Care North, Alberta Health Services, Edmonton, AB, Canada.
- Transplant Services, University of Alberta Hospital, Alberta Health Services, Edmonton, AB, Canada.
Förderung
- Alberta Innovates - Health Solutions
Zitieren
APA
Selzler, A. M., Davoodi, P. M., Klarenbach, S., Lam, N. N., Smith, T., Ackroyd, A., Vandermeer, B., Corradetti, B., Dhaliwal, A., Ferdinand, S., Ikekekpolor, D., Smith, G., Bello, A. K., Wen, K., & Shojai, S. (2026). The Multidisciplinary Support To Access living donor Kidney Transplant (MuST AKT) intervention: A Pilot Randomized Controlled Trial. Transplant International. https://doi.org/10.3389/ti.2026.15472
Vancouver
Selzler AM, Davoodi PM, Klarenbach S, Lam NN, Smith T, Ackroyd A, et al. The Multidisciplinary Support To Access living donor Kidney Transplant (MuST AKT) intervention: A Pilot Randomized Controlled Trial. Transplant International. 2026. doi:10.3389/ti.2026.15472
BibTeX
@article{Selzler2026,
author = {Selzler, Anne-Marie and Davoodi, Parastoo Molla and Klarenbach, Scott and Lam, Ngan N and Smith, Terry and Ackroyd, Abigail and Vandermeer, Ben and Corradetti, Bonnie and Dhaliwal, Aman and Ferdinand, Sharron and Ikekekpolor, Dorothy and Smith, Gordon and Bello, Aminu K and Wen, Kevin and Shojai, Soroush},
title = {The Multidisciplinary Support To Access living donor Kidney Transplant (MuST AKT) intervention: A Pilot Randomized Controlled Trial},
journal = {Transplant International},
year = {2026},
doi = {10.3389/ti.2026.15472}
}
EUVIMED